National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Vestronidase alfa is indicated for the treatment of non-neurological manifestations of MPS VII.

 

NCPE Assessment Process Complete
Rapid review commissioned 09/04/2017
Rapid review completed 22/05/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vestronidase alfa compared with the current standard of care.